Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Lung Cancer

  Free Subscription


Articles published in J Thorac Oncol

Retrieve available abstracts of 505 articles:
HTML format
Text format



Single Articles


    February 2020
  1. GAO S, Li N, Gao S, Xue Q, et al
    Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Feb 6. pii: S1556-0864(20)30057.
    PubMed     Text format     Abstract available


  2. BACKMAN M, La Fleur L, Kurppa P, Djureinovic D, et al
    Characterization of patterns of immune cell infiltration in non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2020 Feb 3. pii: S1556-0864(20)30015.
    PubMed     Text format     Abstract available


  3. POIRIER JT, George J, Owonikoko TK, Berns A, et al
    New approaches to small cell lung cancer therapy : from the laboratory to the clinic.
    J Thorac Oncol. 2020 Feb 1. pii: S1556-0864(20)30056.
    PubMed     Text format     Abstract available


    January 2020
  4. COHEN D, Hondelink LM, Solleveld-Westerink N, Uljee SM, et al
    Optimizing mutation and fusion detection in Non-Small Cell Lung Cancer by sequential DNA and RNA sequencing.
    J Thorac Oncol. 2020 Jan 31. pii: S1556-0864(20)30093.
    PubMed     Text format     Abstract available


  5. TRAVIS WD, Dacic S, Wistuba I, Sholl L, et al
    IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.
    J Thorac Oncol. 2020 Jan 28. pii: S1556-0864(20)30026.
    PubMed     Text format     Abstract available


  6. DAGOGO-JACK I, Schrock AB, Kem M, Jessop N, et al
    Clinicopathologic Characteristics of BRG1-Deficient Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Jan 24. pii: S1556-0864(20)30023.
    PubMed     Text format     Abstract available


  7. ARAI S, Takeuchi S, Fukuda K, Taniguchi H, et al
    Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer.
    J Thorac Oncol. 2020 Jan 20. pii: S1556-0864(20)30022.
    PubMed     Text format     Abstract available


  8. GUISIER F, Dubos-Arvis C, Vinas F, Doubre H, et al
    Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.
    J Thorac Oncol. 2020 Jan 13. pii: S1556-0864(20)30020.
    PubMed     Text format     Abstract available


  9. CHIH-HSIN YANG J, Schuler M, Popat S, Miura S, et al
    Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
    J Thorac Oncol. 2020 Jan 10. pii: S1556-0864(20)30014.
    PubMed     Text format     Abstract available


  10. GAINOR JF, Stevens SE, Willers H, Shih HA, et al
    Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification.
    J Thorac Oncol. 2020;15:e8-e10.
    PubMed     Text format    


  11. WANG X, Lai Y, Dai W, He J, et al
    Mutation Profile of Tibetan Lung Cancer Revealed by Whole Exome Sequencing.
    J Thorac Oncol. 2020;15:e10-e13.
    PubMed     Text format    


  12. VAN EEDEN R, Tunmer M, Geldenhuys A, Nayler S, et al
    Lung Cancer in South Africa.
    J Thorac Oncol. 2020;15:22-28.
    PubMed     Text format    


    December 2019
  13. CHUNG HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, et al
    Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
    J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33850.
    PubMed     Text format     Abstract available


  14. LANTUEJOUL S, Tsao MS, Cooper WA, Girard N, et al
    PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee.
    J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33847.
    PubMed     Text format     Abstract available


  15. HWANG JK, Page BJ, Flynn D, Passmore L, et al
    Validation of the eighth edition TNM lung cancer staging system; a brief report.
    J Thorac Oncol. 2019 Dec 18. pii: S1556-0864(19)33846.
    PubMed     Text format     Abstract available


  16. ALDEA M, Hendriks L, Mezquita L, Jovelet C, et al
    Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression.
    J Thorac Oncol. 2019 Dec 13. pii: S1556-0864(19)33716.
    PubMed     Text format     Abstract available


  17. WANG Z, Duan J, Wang G, Zhao J, et al
    Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors.
    J Thorac Oncol. 2019 Dec 12. pii: S1556-0864(19)33720.
    PubMed     Text format     Abstract available


  18. PARK S, Lee SH, Park K
    In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.
    J Thorac Oncol. 2019;14:e279-e280.
    PubMed     Text format    


  19. LUO P, Lin A, Li K, Wei T, et al
    DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing.
    J Thorac Oncol. 2019;14:e276-e279.
    PubMed     Text format    


  20. PASSIGLIA F, Calandri M, Guerrera F, Malapelle U, et al
    Lung Cancer in Italy.
    J Thorac Oncol. 2019;14:2046-2052.
    PubMed     Text format    


  21. PASTORINO U, Tagliabue E
    Non-Human Determinants of Lung Cancer Outcome: A Target for Inhibition of Pro-Metastatic Effect of Surgery, Triggered by Postoperative Bacterial Pneumonia.
    J Thorac Oncol. 2019;14:2039-2041.
    PubMed     Text format    


    November 2019
  22. WILLIAMS GH, Nicholson AG, Snead DRJ, Thunnissen E, et al
    Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33664.
    PubMed     Text format     Abstract available


  23. NISHIO M, Felip E, Orlov S, Park K, et al
    Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33660.
    PubMed     Text format     Abstract available


  24. LIN SH, Lin Y, Yao L, Kalhor N, et al
    Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer.
    J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33659.
    PubMed     Text format     Abstract available


  25. HUBER RM, Hansen KH, Paz-Ares Rodriguez L, West HL, et al
    Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
    J Thorac Oncol. 2019 Nov 19. pii: S1556-0864(19)33645.
    PubMed     Text format     Abstract available


  26. TAN WL, Chua KLM, Lin CC, Lee VHF, et al
    Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.
    J Thorac Oncol. 2019 Nov 13. pii: S1556-0864(19)33640.
    PubMed     Text format     Abstract available


  27. EDWARDS JG, Chansky K, van Schil P, Nicholson AG, et al
    The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Nov 12. pii: S1556-0864(19)33637.
    PubMed     Text format     Abstract available


  28. BROOKS ED, Verma V, Senan S, De Baere T, et al
    Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Nov 8. pii: S1556-0864(19)33634.
    PubMed     Text format     Abstract available


  29. SHARMA GG, Cortinovis D, Agustoni F, Arosio G, et al
    A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
    J Thorac Oncol. 2019;14:e257-e259.
    PubMed     Text format    


  30. LI J, Li C, Cheng B, He J, et al
    The Relative Impact of Family History of Different Cancers on Lung Cancer Risk.
    J Thorac Oncol. 2019;14:e248-e249.
    PubMed     Text format    


  31. JAZIEH AR, Algwaiz G, Errihani H, Elghissassi I, et al
    Lung Cancer in the Middle East and North Africa Region.
    J Thorac Oncol. 2019;14:1884-1891.
    PubMed     Text format    


    October 2019
  32. LIN JJ, Schoenfeld AJ, Zhu VW, Yeap BY, et al
    Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors.
    J Thorac Oncol. 2019 Oct 26. pii: S1556-0864(19)33573.
    PubMed     Text format     Abstract available


  33. OWONIKOKO TK, Niu H, Nackaerts K, Csoszi T, et al
    Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses.
    J Thorac Oncol. 2019 Oct 23. pii: S1556-0864(19)33572.
    PubMed     Text format     Abstract available


  34. CAIOLA E, Iezzi A, Tomanelli M, Bonaldi E, et al
    LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC.
    J Thorac Oncol. 2019 Oct 18. pii: S1556-0864(19)33568.
    PubMed     Text format     Abstract available


  35. FELIP E, de Braud FG, Maur M, Loong HH, et al
    Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.
    J Thorac Oncol. 2019 Oct 18. pii: S1556-0864(19)33564.
    PubMed     Text format     Abstract available


  36. READY NE, Ott PA, Hellmann MD, Zugazagoitia J, et al
    Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
    J Thorac Oncol. 2019 Oct 17. pii: S1556-0864(19)33531.
    PubMed     Text format     Abstract available


  37. MOHAN S, Foy V, Ayub M, Leong HS, et al
    Profiling of circulating free DNA using targeted and genome wide sequencing in patients with Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Oct 16. pii: S1556-0864(19)33566.
    PubMed     Text format     Abstract available


  38. GASCON P, Nagarkar R, Smakal M, Syrigos KN, et al
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin alfa for Chemotherapy-Induced Anemia in Patients With Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Oct 16. pii: S1556-0864(19)33563.
    PubMed     Text format     Abstract available


  39. HAN D, Heuvelmans MA, van der Aalst CM, van Smoorenburg LH, et al
    New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study.
    J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33521.
    PubMed     Text format     Abstract available


  40. ALMOTLAK AA, Farooqui M, Siegfried JM
    Inhibiting pathways predicted from a steroid hormone gene signature yields synergistic anti-tumor effects in non-small cell lung cancer.
    J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33523.
    PubMed     Text format     Abstract available


  41. CHIH-HSIN YANG J, Cheng Y, Murakami H, Yang PC, et al
    A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33332.
    PubMed     Text format    


  42. ZUGAZAGOITIA J, Liu Y, Toki M, McGuire J, et al
    Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33342.
    PubMed     Text format     Abstract available


  43. WELSH JW, Heymach JV, Chen D, Verma V, et al
    Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33525.
    PubMed     Text format     Abstract available


  44. BROWN H, Vansteenkiste J, Nakagawa K, Cobo M, et al
    Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33334.
    PubMed     Text format     Abstract available


  45. SANCHIS-BORJA M, Parrot A, Sroussi D, Rivin Del Campo E, et al
    Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung Cancer.
    J Thorac Oncol. 2019;14:e224-e226.
    PubMed     Text format    


  46. GUAN R, Lin A, Luo P, Zhang J, et al
    Association between Circulating Inflammatory Proteins and Clinical Prognosis in Chinese Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e222-e224.
    PubMed     Text format    


  47. ARRIETA O, Zatarain-Barron ZL, Aldaco F, Barron F, et al
    Lung Cancer in Mexico.
    J Thorac Oncol. 2019;14:1695-1700.
    PubMed     Text format    


  48. GRANNIS FW JR
    Lung Cancer Incidence and Mortality with Extended Follow-up during Screening.
    J Thorac Oncol. 2019;14:1692-1694.
    PubMed     Text format    


    September 2019
  49. HSU CC, Liao BC, Liao WY, Markovets A, et al
    Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer.
    J Thorac Oncol. 2019 Sep 23. pii: S1556-0864(19)33307.
    PubMed     Text format     Abstract available


  50. GAGNE A, Wang E, Bastien N, Orain M, et al
    Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines.
    J Thorac Oncol. 2019 Sep 5. pii: S1556-0864(19)33186.
    PubMed     Text format     Abstract available


  51. FANG W, Huang Y, Gan J, Hong S, et al
    A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.
    J Thorac Oncol. 2019;14:e201-e202.
    PubMed     Text format    


  52. BUROTTO M, Aren O, Renner A, Samtani S, et al
    Lung Cancer in Chile.
    J Thorac Oncol. 2019;14:1504-1509.
    PubMed     Text format    


  53. ARENBERG D
    Micronodules Detected on Lung Cancer Screening CT Scans.
    J Thorac Oncol. 2019;14:1501-1503.
    PubMed     Text format    


    August 2019
  54. MORENO AC, Fellman B, Hobbs BP, Liao Z, et al
    Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Aug 31. pii: S1556-0864(19)33191.
    PubMed     Text format     Abstract available


  55. GILL RR, Tsao AS, Kindler HL, Richards WG, et al
    Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Me
    J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30695.
    PubMed     Text format     Abstract available


  56. SEN T, Della Corte CM, Milutinovic S, Cardnell RJ, et al
    Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
    J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30692.
    PubMed     Text format     Abstract available


  57. OHUE Y, Kurose K, Karasaki T, Isobe M, et al
    Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2019 Aug 23. pii: S1556-0864(19)30691.
    PubMed     Text format     Abstract available


  58. HORN L, Whisenant JG, Wakelee H, Reckamp KL, et al
    Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.
    J Thorac Oncol. 2019 Aug 22. pii: S1556-0864(19)30665.
    PubMed     Text format     Abstract available


  59. PARK BJ, Kim TH, Shin S, Kim HK, et al
    Recommended change in the N descriptor proposed by the International Association for the Study of Lung Cancer: a validation study.
    J Thorac Oncol. 2019 Aug 20. pii: S1556-0864(19)30670.
    PubMed     Text format     Abstract available


  60. SPAGGIARI L, Sedda G, Maisonneuve P, Tessitore A, et al
    A brief report on survival after robotic lobectomy for early-stage lung cancer.
    J Thorac Oncol. 2019 Aug 19. pii: S1556-0864(19)30666.
    PubMed     Text format     Abstract available


  61. FU F, Zhang Y, Wen Z, Zheng D, et al
    Distinct prognostic factors in patients with stage I non-small cell lung cancer with radiologic part solid or solid lesions.
    J Thorac Oncol. 2019 Aug 19. pii: S1556-0864(19)30664.
    PubMed     Text format     Abstract available


  62. DINGEMANS AC, Hendriks LEL, Berghmans T, Levy A, et al
    Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.
    J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655.
    PubMed     Text format     Abstract available


  63. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Negative Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Through Host Toll-like Receptor 4 Activation.
    J Thorac Oncol. 2019 Aug 2. pii: S1556-0864(19)30653.
    PubMed     Text format     Abstract available


  64. STIRLING R, Zalcberg J
    Peeling the Onion of Health Care Disparity in Lung Cancer.
    J Thorac Oncol. 2019;14:e167-e168.
    PubMed     Text format    


  65. JAIN A, Fujioka N, Patel M
    Immune Checkpoint Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Report of Two Cases.
    J Thorac Oncol. 2019;14:e165-e167.
    PubMed     Text format    


  66. WATANABE Y, Kikuchi R, Iwai Y, Ito M, et al
    Varicella Zoster Virus Encephalitis Mimicking Nivolumab-Induced Autoimmune Neuropathy in a Patient with Lung Cancer.
    J Thorac Oncol. 2019;14:e163-e165.
    PubMed     Text format    


  67. ZHOU H, Liu J, Zhang Y, Huang Y, et al
    Autoimmune Diseases and Lung Cancer: A Mendelian Randomization Study.
    J Thorac Oncol. 2019;14:e161-e163.
    PubMed     Text format    


  68. ZWITTER M, Cufer T, Vrankar M, Kern I, et al
    Lung Cancer in Slovenia.
    J Thorac Oncol. 2019;14:1327-1331.
    PubMed     Text format    


  69. BERNICKER EH, Quigley EMM
    The Gut Microbiome Influences Responses to Programmed Death 1 Therapy in Chinese Lung Cancer Patients - the Benefits of Diversity.
    J Thorac Oncol. 2019;14:1319-1322.
    PubMed     Text format    


  70. GAY CM, Byers LA
    PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?
    J Thorac Oncol. 2019;14:1323-1326.
    PubMed     Text format    


    July 2019
  71. MAKIMOTO G, Ohashi K, Tomida S, Nishii K, et al
    Brief Report: Rapid Acquisition of Alectinib Resistance in ALK-positive Lung Cancer with High Tumor Mutation Burden.
    J Thorac Oncol. 2019 Jul 30. pii: S1556-0864(19)30602.
    PubMed     Text format     Abstract available


  72. YANG SC, Kuo CW, Lai WW, Lin CC, et al
    Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up.
    J Thorac Oncol. 2019 Jul 25. pii: S1556-0864(19)30588.
    PubMed     Text format     Abstract available


  73. CONDE E, Hernandez S, Martinez R, Angulo B, et al
    Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.
    J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562.
    PubMed     Text format     Abstract available


  74. EDELMAN MJ, Redman MW, Albain KS, McGary EC, et al
    Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study).
    J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30557.
    PubMed     Text format     Abstract available


  75. BENITEZ JC, Mezquita L, Colle R, Tselikas KL, et al
    Hepatic Intra-Arterial Chemotherapy with Immunotherapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30556.
    PubMed     Text format    


  76. FUJINO T, Kobayashi Y, Suda K, Koga T, et al
    Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
    J Thorac Oncol. 2019 Jul 3. pii: S1556-0864(19)30551.
    PubMed     Text format     Abstract available


  77. CANEPA M, Patel NR, Griffith RC, Ng TT, et al
    KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e153-e155.
    PubMed     Text format    


  78. WANG H, Zhang L, Liu W
    Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e141-e143.
    PubMed     Text format    


  79. HO C, Lefresne S, Liberman M, McGuire A, et al
    Lung Cancer in Canada.
    J Thorac Oncol. 2019;14:1128-1133.
    PubMed     Text format    


  80. FOSTER CC, Pitroda SP, Weichselbaum RR
    Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jul 1. pii: S1556-0864(19)30410.
    PubMed     Text format    


  81. REKHTMAN N, Travis WD
    Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity.
    J Thorac Oncol. 2019;14:1125-1127.
    PubMed     Text format    


  82. LAI WV, Rudin CM
    Analyzing the Thin Tail: Searching for Biomarkers of Exceptional Survival in SCLC.
    J Thorac Oncol. 2019;14:1122-1124.
    PubMed     Text format    


  83. KOUNO S, Atagi S
    Immunotherapy for NSCLC With Brain Metastases: What Can We Learn From Real-World Data?
    J Thorac Oncol. 2019;14:1119-1121.
    PubMed     Text format    


    June 2019
  84. BAUER TM, Besse B, Martinez-Marti A, Trigo JM, et al
    Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30503.
    PubMed     Text format     Abstract available


  85. NAITO T, Udagawa H, Sato J, Horinouchi H, et al
    A minimum of 100 tumor cells in a single biopsy sample is required to assess programmed cell death ligand 1 expression in predicting patient response to nivolumab treatment in non-squamous non-small cell lung carcinoma.
    J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30501.
    PubMed     Text format     Abstract available


  86. CHAE YK, Viveiros P, Lopes G, Sukhadia B, et al
    Clinical and immunological implications of frameshift mutations in lung cancer.
    J Thorac Oncol. 2019 Jun 22. pii: S1556-0864(19)30496.
    PubMed     Text format     Abstract available


  87. MUNDEN RF, Chiles C, Boiselle PM, Sicks JD, et al
    Micronodules Detected on CT during the NLST: Prevalence and Relation to Positive Studies and Lung Cancer.
    J Thorac Oncol. 2019 Jun 20. pii: S1556-0864(19)30481.
    PubMed     Text format     Abstract available


  88. GUO R, Berry LD, Aisner DL, Sheren J, et al
    MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30474.
    PubMed     Text format     Abstract available


  89. BALATA H, Fong KM, Hendriks LE, Lam S, et al
    Prevention and Early Detection for Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30476.
    PubMed     Text format     Abstract available


  90. BLACK WC, Chiles C, Church TR, Gareen IF, et al
    Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial National Lung Screening Trial Writing Team (1).
    J Thorac Oncol. 2019 Jun 13. pii: S1556-0864(19)30473.
    PubMed     Text format     Abstract available


  91. IAMS WT, Shiuan E, Meador CB, Roth M, et al
    Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes.
    J Thorac Oncol. 2019 Jun 12. pii: S1556-0864(19)30463.
    PubMed     Text format     Abstract available


  92. AGGARWAL C, Redman MW, Lara PN Jr, Borghaei H, et al
    Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30462.
    PubMed     Text format     Abstract available


  93. KIM Y, Kim CH, Lee HY, Lee SH, et al
    Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30454.
    PubMed     Text format     Abstract available


  94. LAIRD J, Lok BH, Carney B, Kossatz S, et al
    PET Imaging of a [(18)F]-radiolabeled PARP Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in Small Cell Lung Cancer Patient-Derived Xenografts.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30453.
    PubMed     Text format     Abstract available


  95. GIAJLEVRA N, Levra MG, Durieux V, Novello S, et al
    Defining synchronous oligometastatic non-small cell lung cancer: a systematic review.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30458.
    PubMed     Text format     Abstract available


  96. GONG L, Qin J, Xie F, Han N, et al
    The Evolutionary Difference Between Extracranial Lesions and Leptomeningeal Metastasis in a Patient With Afatinib-Resistant Lung Cancer.
    J Thorac Oncol. 2019;14:e120-e123.
    PubMed     Text format    


  97. JAZIEH AR, Algwaiz G, Alshehri SM, Alkattan K, et al
    Lung Cancer in Saudi Arabia.
    J Thorac Oncol. 2019;14:957-962.
    PubMed     Text format    


  98. ADJEI AA
    Lung Cancer Worldwide.
    J Thorac Oncol. 2019;14:956.
    PubMed     Text format    


  99. MILLER AB
    Improving Surveillance following Treatment for Lung Cancer.
    J Thorac Oncol. 2019;14:955.
    PubMed     Text format    


  100. RUTKOWSKI J, Saad ED, Burzykowski T, Buyse M, et al
    Chronological Trends in Progression-free, Overall and Post-progression Survival in First-line Therapy for Advanced Non-small-cell Lung Cancer.
    J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30415.
    PubMed     Text format     Abstract available


  101. SHEPSHELOVICH D, Xu W, Lu L, Fares A, et al
    Body mass index (BMI), BMI change, and overall survival in small cell and non-small cell lung cancer patients: a pooled analysis of the International Lung Cancer Consortium.
    J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30416.
    PubMed     Text format     Abstract available


  102. HANDRA-LUCA A
    Alveolar Septa Muscle: Subclinical Pulmonary Hypertension-Related Change or Malformation?
    J Thorac Oncol. 2019;14:e124-e125.
    PubMed     Text format    


  103. ROTHSCHILD SI
    KRAS and Immune Checkpoint Inhibitors-Serendipity Raising Expectations.
    J Thorac Oncol. 2019;14:951-954.
    PubMed     Text format    


    May 2019
  104. LANGER CJ, Redman MW, Wade JL 3rd, Aggarwal C, et al
    Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
    J Thorac Oncol. 2019 May 31. pii: S1556-0864(19)30414.
    PubMed     Text format     Abstract available


  105. PARK S, Lee H, Lee B, Lee SH, et al
    DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer.
    J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30381.
    PubMed     Text format     Abstract available


  106. GOMEZ DR, Rimner A, Simone CB 2nd, Cho BCJ, et al
    The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applie
    J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30380.
    PubMed     Text format     Abstract available


  107. SPIGEL DR, McCleod M, Jotte RM, Einhorn L, et al
    Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged >/=70 Years or with Poor Performance Status (CheckMate 153).
    J Thorac Oncol. 2019 May 20. pii: S1556-0864(19)30376.
    PubMed     Text format     Abstract available


  108. LEE Y, Kim TM, Kim DW, Kim S, et al
    Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30369.
    PubMed     Text format     Abstract available


  109. FLIPPOT R, Biondani P, Auclin E, Xiao D, et al
    Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases.
    J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30370.
    PubMed     Text format     Abstract available


  110. MURPHY SJ, Harris FR, Kosari F, Terra S, et al
    Using genomics to differentiate multiple primaries from metastatic lung cancer.
    J Thorac Oncol. 2019 May 16. pii: S1556-0864(19)30374.
    PubMed     Text format     Abstract available


  111. MUPPA P, Parrilha Terra SB, Sharma A, Mansfield AS, et al
    Immune Cell Infiltration May be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
    J Thorac Oncol. 2019 May 9. pii: S1556-0864(19)30356.
    PubMed     Text format     Abstract available


  112. TREMBLAY A, Taghizadeh N, Huang J, Kasowski D, et al
    A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program.
    J Thorac Oncol. 2019 May 8. pii: S1556-0864(19)30359.
    PubMed     Text format     Abstract available


  113. CANNON-ALBRIGHT LA, Carr SR, Akerley W
    Population-based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer.
    J Thorac Oncol. 2019 May 7. pii: S1556-0864(19)30316.
    PubMed     Text format     Abstract available


  114. VARGHESE C, Rajagopalan S, Karwoski RA, Bartholmai BJ, et al
    Computed Tomography based Score Indicative of Lung Cancer Aggression (SILA) Predicts the Degree of Histological Tissue Invasion and Patient Survival in Lung Adenocarcinoma Spectrum.
    J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30355.
    PubMed     Text format     Abstract available


  115. THOMAS A, Vilimas R, Trindade C, Erwin-Cohen R, et al
    Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study.
    J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30361.
    PubMed     Text format     Abstract available


  116. KATSUMATA S, Aokage K, Ishii G, Nakasone S, et al
    Prognostic impact of the number of metastatic lymph nodes on the eighth edition of the TNM classification of non-small cell lung cancer.
    J Thorac Oncol. 2019 May 2. pii: S1556-0864(19)30313.
    PubMed     Text format     Abstract available


  117. MEHLMAN C, Chaabane N, Lacave R, Kerrou K, et al
    Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
    J Thorac Oncol. 2019;14:e95-e96.
    PubMed     Text format    


  118. ZHANG J, Wang J, Qian Z, Han Y, et al
    CCR5 is Associated With Immune Cell Infiltration and Prognosis of Lung Cancer.
    J Thorac Oncol. 2019;14:e102-e103.
    PubMed     Text format    


  119. AHN MJ
    Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?
    J Thorac Oncol. 2019;14:766-767.
    PubMed     Text format    


  120. CHIAPPETTA M, Petracca Ciavarella L, Margaritora S
    Can Pemetrexed Also Have a Potential Role Preoperatively in the Management of Advanced Thymic Epithelial Tumors?
    J Thorac Oncol. 2019;14:e89.
    PubMed     Text format    


  121. MITSUDOMI T
    BRAF Fusion - Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2019;14:764-765.
    PubMed     Text format    


  122. GROEN HJM, Hiltermann TJN
    Air Pollution and Adenocarcinoma in Never-Smokers.
    J Thorac Oncol. 2019;14:761-763.
    PubMed     Text format    


  123. DAVIES KD, Villalobos VM, Aisner DL
    Ready or Not, Here I Come: Inflammatory Myofibroblastic Tumors With Kinase Alterations Revealed Through Molecular Hide and Seek.
    J Thorac Oncol. 2019;14:758-760.
    PubMed     Text format    


    April 2019
  124. JIN Y, Dong H, Xia L, Yang Y, et al
    The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients.
    J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30286.
    PubMed     Text format     Abstract available


  125. REMON J, Reguart N, Auclin E, Besse B, et al
    Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?
    J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30202.
    PubMed     Text format    


  126. HUNG RJ, Spitz MR, Houlston RS, Schwartz AG, et al
    Lung Cancer Risk in Never Smokers of European Descent is Associated with Genetic Variation in the 5P15.33 TERT-CLPTM1L Region.
    J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30289.
    PubMed     Text format     Abstract available


  127. DAI J, Liu M, Yang Y, Li Q, et al
    Optimal Lymph Nodes Examination and Adjuvant Chemotherapy for Stage I Lung Cancer.
    J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30290.
    PubMed     Text format     Abstract available


  128. MANOHARAN P, Salem A, Mistry H, Gornall M, et al
    [18F]fludeoxyglucose PET/CT in small-cell lung cancer: Analysis of the CONVERT randomized controlled trial.
    J Thorac Oncol. 2019 Apr 16. pii: S1556-0864(19)30282.
    PubMed     Text format     Abstract available


  129. REMON J, Ahn MJ, Girard N, Johnson M, et al
    Advanced Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Apr 16. pii: S1556-0864(19)30280.
    PubMed     Text format     Abstract available


  130. SORICH MJ, Rowland A, Karapetis CS, Hopkins AM, et al
    Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.
    J Thorac Oncol. 2019 Apr 15. pii: S1556-0864(19)30285.
    PubMed     Text format     Abstract available


  131. MICHELS S, Massuti B, Schildhaus HU, Franklin J, et al
    Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial.
    J Thorac Oncol. 2019 Apr 9. pii: S1556-0864(19)30276.
    PubMed     Text format     Abstract available


  132. KRATZ JR, Haro GJ, Cook NR, He J, et al
    Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    J Thorac Oncol. 2019 Apr 5. pii: S1556-0864(19)30270.
    PubMed     Text format     Abstract available


  133. MEANEY C, Mitchell KA, Zingone A, Brown D, et al
    Circulating Inflammation Proteins Associated with Lung Cancer in African Americans.
    J Thorac Oncol. 2019 Apr 3. pii: S1556-0864(19)30269.
    PubMed     Text format     Abstract available


  134. LI C, Liang H, Zhong N, He J, et al
    Optimal Starting Age for Lung Cancer Screening With Low-Dose Computed Tomography: A Population Level Analysis.
    J Thorac Oncol. 2019;14:e82-e84.
    PubMed     Text format    


  135. QIN J, Wang J, Lin X, Wang J, et al
    Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e65-e68.
    PubMed     Text format    


  136. ARJYAL L
    Concurrent Chemoradiation in Elderly Patients with Limited-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e63.
    PubMed     Text format    


  137. LU S, Li Z
    Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:580-582.
    PubMed     Text format    


  138. WANG Z, Wu YL
    Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib.
    J Thorac Oncol. 2019;14:e81-e82.
    PubMed     Text format    


  139. CHRISTODOULOU M, Faivre-Finn C
    Author's Reply to the: Letter to the Editor.
    J Thorac Oncol. 2019;14:e63-e64.
    PubMed     Text format    


  140. MACKINTOSH JA, Marshall HM, Fong KM
    A Targeted Approach to the Complications of Targeted Therapy.
    J Thorac Oncol. 2019;14:577-579.
    PubMed     Text format    


  141. MOLNAR TF, Szipocs A, Szalai Z
    Neoadjuvant Crizotinib for ALK Re-arranged NSCLC?
    J Thorac Oncol. 2019;14:574-576.
    PubMed     Text format    


    March 2019
  142. BOUSEMA JE, van Dorp M, Noyez VJJM, Dijkgraaf MGW, et al
    Unforeseen N2 disease following negative endosonography with or without confirmatory mediastinoscopy in resectable non-small cell lung cancer: a systematic review and meta-analysis.
    J Thorac Oncol. 2019 Mar 21. pii: S1556-0864(19)30211.
    PubMed     Text format    


  143. CAMIDGE DR, Dziadziuszko R, Peters S, Mok T, et al
    Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study.
    J Thorac Oncol. 2019 Mar 19. pii: S1556-0864(19)30210.
    PubMed     Text format     Abstract available


  144. OSAROGIAGBON RU, Veronesi G, Fang W, Ekman S, et al
    Early Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Mar 6. pii: S1556-0864(19)30199.
    PubMed     Text format     Abstract available


  145. LEE J, Maeng CH, Song JU
    The Role of Prophylactic Cranial Irradiation in Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2019;14:e60-e61.
    PubMed     Text format    


  146. KOGURE Y, Ishii Y, Oki M
    Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    J Thorac Oncol. 2019;14:e55-e57.
    PubMed     Text format    


  147. LAM S
    Lung Cancer Screening in Never-Smokers.
    J Thorac Oncol. 2019;14:336-337.
    PubMed     Text format    


  148. FERRARA R, Caramella C, Besse B, Champiat S, et al
    Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
    J Thorac Oncol. 2019;14:328-331.
    PubMed     Text format    


  149. RAMAEKERS B, De Ruysscher D
    Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?
    J Thorac Oncol. 2019;14:326-327.
    PubMed     Text format    


  150. BUCKNELL NW, Ball D
    PCI in Small Cell-Review the Cohorts.
    J Thorac Oncol. 2019;14:e59-e60.
    PubMed     Text format    


  151. RIHAWI K, Giannarelli D, Galetta D, Delmonte A, et al
    BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.
    J Thorac Oncol. 2019;14:e57-e59.
    PubMed     Text format    


  152. LE T, Minna JD, Gerber DE
    Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?
    J Thorac Oncol. 2019;14:332-335.
    PubMed     Text format    


    February 2019
  153. DZIADZIUSZKO R, Smit EF, Dafni U, Wolf J, et al
    Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP).
    J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30148.
    PubMed     Text format     Abstract available


  154. SHUKUYA T, Yamada T, Koenig MJ, Xu J, et al
    The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non-small cell lung cancer.
    J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30150.
    PubMed     Text format     Abstract available


  155. CAMIDGE DR, Kim EE, Usari T, Polli A, et al
    Renal Effects of Crizotinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Feb 26. pii: S1556-0864(19)30146.
    PubMed     Text format     Abstract available


  156. HENDRIKS LEL, Henon C, Auclin E, Mezquita L, et al
    Outcome of non-small cell lung cancer patients with brain metastases treated with checkpoint inhibitors.
    J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30117.
    PubMed     Text format     Abstract available


  157. NEGRAO MV, Lam VK, Reuben A, Rubin ML, et al
    PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.
    J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30116.
    PubMed     Text format     Abstract available


  158. LIZEE T, Basch E, Tremolieres P, Voog E, et al
    Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.
    J Thorac Oncol. 2019 Feb 15. pii: S1556-0864(19)30113.
    PubMed     Text format     Abstract available


  159. AGGARWAL R, Lam AC, McGregor M, Menezes R, et al
    Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30112.
    PubMed     Text format     Abstract available


  160. HSU WH, Zhao X, Zhu J, Kim IK, et al
    Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30108.
    PubMed     Text format     Abstract available


  161. LEE JW, Zhang Y, Eoh KJ, Sharma R, et al
    The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30111.
    PubMed     Text format     Abstract available


  162. ZIMMERMAN S, Das A, Wang S, Julian R, et al
    2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Feb 11. pii: S1556-0864(19)30099.
    PubMed     Text format     Abstract available


  163. JEANSON A, Tomasini P, Souquet-Bressand M, Brandone N, et al
    Brief report: efficacy of immune checkpoint inhibitors in KRAS-mutant Non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2019 Feb 6. pii: S1556-0864(19)30040.
    PubMed     Text format     Abstract available


  164. EL OSTA B, Behera M, Kim S, Berry LD, et al
    Characteristics and outcomes of patients with metastatic KRAS mutant lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.
    J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30097.
    PubMed     Text format     Abstract available


  165. ZHAO X, Kallakury B, Chahine JJ, Hartmann D, et al
    Surgical resection of small cell lung carcinoma: prognostic factors and the tumor microenvironment.
    J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30096.
    PubMed     Text format     Abstract available


  166. IJSSELDIJK MA, Shoni M, Siegert C, Wiering BM, et al
    Survival after SBRT for Clinically diagnosed or Biopsy-proven Early-stage Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2019 Feb 2. pii: S1556-0864(19)30094.
    PubMed     Text format     Abstract available


  167. TABBO F, D'Aveni A, Tota D, Pignataro D, et al
    Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread?
    J Thorac Oncol. 2019;14:e38-e40.
    PubMed     Text format    


  168. VARKARIS A, Sehgal K, Rangachari D, Costa DB, et al
    Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.
    J Thorac Oncol. 2019;14:e34-e36.
    PubMed     Text format    


  169. WATANABE K, Kage H, Shinozaki-Ushiku A, Kohsaka S, et al
    Spontaneous Transdifferentiation from Small Cell Lung Carcinoma to Squamous Cell Carcinoma.
    J Thorac Oncol. 2019;14:e31-e34.
    PubMed     Text format    


  170. BOGART JA, Mix M
    Management of the Brain in Small Cell Lung Cancer: Are Patients Paying a Lot Now Instead of a Little Later?
    J Thorac Oncol. 2019;14:153-156.
    PubMed     Text format    


  171. TSOU TC, Gowen K, Ali SM, Miller VA, et al
    Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.
    J Thorac Oncol. 2019;14:e29-e30.
    PubMed     Text format    


  172. GOLDMAN JW, Garon EB
    Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story.
    J Thorac Oncol. 2019;14:160-162.
    PubMed     Text format    


  173. CARBONE M, Yang H, Gaudino G
    Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?
    J Thorac Oncol. 2019;14:157-159.
    PubMed     Text format    


    January 2019
  174. KIM ES, Roy UB, Ersek JL, King J, et al
    Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
    J Thorac Oncol. 2019 Jan 29. pii: S1556-0864(19)30003.
    PubMed     Text format    


  175. RECK M, Horn L, Novello S, Barlesi F, et al
    Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small-Cell Lung Cancer.
    J Thorac Oncol. 2019 Jan 21. pii: S1556-0864(19)30029.
    PubMed     Text format     Abstract available


  176. TSENG CH, Tsuang BJ, Chiang CJ, Ku KC, et al
    The relationship between air pollution and lung cancer in non-smokers in Taiwan.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30026.
    PubMed     Text format     Abstract available


  177. DAGOGO-JACK I, Rooney M, Nagy RJ, Lin JJ, et al
    Molecular Analysis of Plasma from Patients with ROS1-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30027.
    PubMed     Text format     Abstract available


  178. PUJOL JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al
    A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30025.
    PubMed     Text format     Abstract available


  179. DAGOGO-JACK I, Robinson H, Mino-Kenudson M, Farago AF, et al
    Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients with Minimal Smoking History.
    J Thorac Oncol. 2019 Jan 17. pii: S1556-0864(19)30024.
    PubMed     Text format     Abstract available


  180. WU YL, Lu S, Cheng Y, Zhou C, et al
    Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial.
    J Thorac Oncol. 2019 Jan 16. pii: S1556-0864(19)30020.
    PubMed     Text format     Abstract available


  181. QUINTANAL-VILLALONGA A, Molina-Pinelo S, Cirauqui C, Ojeda-Marquez L, et al
    FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy.
    J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30008.
    PubMed     Text format     Abstract available


  182. DAVIES KD, Lomboy A, Lawrence CA, Yourshaw M, et al
    Brief Report: DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer.
    J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30007.
    PubMed     Text format     Abstract available


  183. LU S, Yu Y, Li Z, Yu R, et al
    Brief Report: EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
    J Thorac Oncol. 2019 Jan 2. pii: S1556-0864(18)33515.
    PubMed     Text format     Abstract available


  184. LEE YL, Hsu JF, Yang CJ
    Tracheoesophageal Fistula in a Patient with Advanced Non-Small Cell Lung Cancer Who Received Chemoradiotherapy and Ramucirumab.
    J Thorac Oncol. 2019;14:e17-e18.
    PubMed     Text format    


  185. VAN LOON J, Dingemans AC
    Is Concurrent Chemoradiotherapy Also the Best Treatment for Elderly Patients with Limited-Stage Small Cell Lung Cancer? - What the CONVERT Data Can Tell Us.
    J Thorac Oncol. 2019;14:13-15.
    PubMed     Text format    


  186. ABADA PB
    Tracheoesophageal Fistula in a Patient With Advanced NSCLC Who Received Chemoradiotherapy and Ramucirumab.
    J Thorac Oncol. 2019;14:e19.
    PubMed     Text format    


  187. DRESLER C, Warren GW, Arenberg D, Yang P, et al
    Indeed, Nuance Matters.
    J Thorac Oncol. 2019;14:e16-e17.
    PubMed     Text format    


  188. STIEFEL F, Bourquin C
    Nuance Matters.
    J Thorac Oncol. 2019;14:e15.
    PubMed     Text format    


  189. MCCOACH CE
    A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy.
    J Thorac Oncol. 2019;14:8-10.
    PubMed     Text format    


  190. DAVID EA, Atay SM, McFadden PM, Kim AW, et al
    Sublobar or Suboptimal: Does Tumor Spread through Air Spaces Signify the End of Sublobar Resections for T1N0 Adenocarcinomas?
    J Thorac Oncol. 2019;14:11-12.
    PubMed     Text format    


    December 2018
  191. PACHECO JM, Gao D, Smith D, Purcell WT, et al
    Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer.
    J Thorac Oncol. 2018 Dec 29. pii: S1556-0864(18)33533.
    PubMed     Text format     Abstract available


  192. YATABE Y, Dacic S, Borczuk AC, Warth A, et al
    Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
    J Thorac Oncol. 2018 Dec 17. pii: S1556-0864(18)33514.
    PubMed     Text format     Abstract available


  193. IAMS WT, Beckermann KE, Almodovar K, Hernandez J, et al
    Small cell lung cancer transformation as a mechanism of resistance to PD-1 therapy in KRAS mutant lung adenocarcinoma: A report of two cases.
    J Thorac Oncol. 2018 Dec 10. pii: S1556-0864(18)33511.
    PubMed     Text format    


  194. SEIJO LM, Peled N, Ajona D, Boeri M, et al
    Biomarkers in lung cancer screening: achievements, promises and challenges.
    J Thorac Oncol. 2018 Dec 4. pii: S1556-0864(18)33501.
    PubMed     Text format     Abstract available


  195. YANG JC, Gadgeel SM, Sequist LVD, Wu CL, et al
    Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Sensitizing EGFR Mutation.
    J Thorac Oncol. 2018 Dec 4. pii: S1556-0864(18)33506.
    PubMed     Text format     Abstract available


    November 2018
  196. HECHTNER M, Eichler M, Wehler B, Buhl R, et al
    Quality of life in Non-Small Cell Lung Cancer survivors - a multicenter cross-sectional study.
    J Thorac Oncol. 2018 Nov 30. pii: S1556-0864(18)33497.
    PubMed     Text format     Abstract available


  197. SURESH K, Psoter KJ, Voong KR, Shankar B, et al
    Impact of Checkpoint Inhibitor Pneumonitis on Survival in Non-Small Cell Lung Cancer Patients receiving Immune Checkpoint Immunotherapy.
    J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33493.
    PubMed     Text format     Abstract available


  198. ERNANI V, Appiah AK, Marr A, Zhang C, et al
    Adjuvant Systemic Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC) Treated with Stereotactic Body Radiation Therapy (SBRT).
    J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33495.
    PubMed     Text format     Abstract available


  199. QU Y, Emoto K, Eguchi T, Aly RG, et al
    Pathologic assessment after neoadjuvant chemotherapy for non-small cell lung cancer: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma.
    J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33494.
    PubMed     Text format     Abstract available


  200. LICHTENSTEIN M, Nipp RD, Muzikansky A, Goodwin K, et al
    Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Nov 23. pii: S1556-0864(18)33454.
    PubMed     Text format     Abstract available


  201. KARACHALIOU N, Bracht JWP, Bruno MF, Drozdowskyj A, et al
    BRIEF REPORT: Association of PALB2 Messenger RNA Expression with platinum-docetaxel efficacy in advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Nov 22. pii: S1556-0864(18)33450.
    PubMed     Text format     Abstract available


  202. FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
    Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy: A multicenter retrospective cohort study.
    J Thorac Oncol. 2018 Nov 20. pii: S1556-0864(18)33418.
    PubMed     Text format     Abstract available


  203. KANG HR, Cho JY, Lee SH, Lee YJ, et al
    Role of low-dose computerized tomography in lung cancer screening among never-smokers.
    J Thorac Oncol. 2018 Nov 13. pii: S1556-0864(18)33417.
    PubMed     Text format     Abstract available


  204. ZHANG C, Li SL, Nie Q, Dong S, et al
    Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer with ALK-rearrangement: A Brief Report.
    J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33410.
    PubMed     Text format     Abstract available


  205. SINICROPI-YAO SL, Amann JM, Lopez DLY, Cerciello F, et al
    Co-expression analysis reveals mechanisms underlying the varied roles of NOTCH1 in non-small cell lung cancer.
    J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33411.
    PubMed     Text format     Abstract available


  206. BLAAUWGEERS H, Damhuis R, Lissenberg-Witte B, de Langen AJ, et al
    A population-based study of outcomes in surgically resected T3N0 non-small cell lung cancer in the Netherlands, defined using TNM-7 and TNM-8; justification of changes and an argument to incorporate histology in the staging algorithm?
    J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33413.
    PubMed     Text format     Abstract available


  207. SHIN DW, Cho J, Noh JM, Han H, et al
    Disparities in the diagnosis and treatment of lung cancer among people with disabilities.
    J Thorac Oncol. 2018 Nov 2. pii: S1556-0864(18)33407.
    PubMed     Text format     Abstract available


  208. RICCIUTI B, Marcomigni L, Metro G, Bellezza G, et al
    Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib.
    J Thorac Oncol. 2018;13:e220-e222.
    PubMed     Text format    


  209. YOSHIDA H, Ooi M, Kim YH
    Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.
    J Thorac Oncol. 2018;13:e219-e220.
    PubMed     Text format    


    October 2018
  210. KIM Y, Lee B, Shim JH, Lee SH, et al
    Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33383.
    PubMed     Text format     Abstract available


  211. GELSOMINO F, Facchini G, Barbera MA, Lamberti G, et al
    Complete recalcification following arterial embolization of massive osteolytic bone metastasis from non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33384.
    PubMed     Text format    


  212. SCHROCK AB, Welsh A, Chung JH, Pavlick D, et al
    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Oct 24. pii: S1556-0864(18)33205.
    PubMed     Text format     Abstract available


  213. BASU ROY U, King-Kallimanis BL, Kluetz PG, Selig W, et al
    Learning from Patients: Reflections on Use of Patient-Reported Outcomes in Lung Cancer Trials.
    J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33052.
    PubMed     Text format    


  214. LAMMERS A, Slatore CG, Fromme EK, Vranas K, et al
    Association of Early Palliative Care with Chemotherapy Intensity in Patients with Advanced Stage Lung Cancer : A National Cohort Study.
    J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33184.
    PubMed     Text format    


  215. OKAMI J, Shintani Y, Okumura M, Ito H, et al
    Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese Joint committee of Lung Cancer Registry database in 2010.
    J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33180.
    PubMed     Text format     Abstract available


  216. READY N, Farago AF, de Braud F, Atmaca A, et al
    Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032.
    J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33181.
    PubMed     Text format     Abstract available


  217. CHAE YK, Oh MS
    Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions.
    J Thorac Oncol. 2018 Oct 5. pii: S1556-0864(18)33174.
    PubMed     Text format     Abstract available


  218. SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
    Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33173.
    PubMed     Text format     Abstract available


  219. LEVY A, Le Pechoux C, Mistry H, Martel-Lafay I, et al
    Prophylactic cranial irradiation for limited-stage small-cell lung cancer patients: secondary findings from the prospective randomized phase 3 CONVERT trial.
    J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33171.
    PubMed     Text format     Abstract available


  220. CHU X, Li Y, Zhu Z
    A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib.
    J Thorac Oncol. 2018;13:e211-e214.
    PubMed     Text format    


  221. TAKIGAWA N
    How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?
    J Thorac Oncol. 2018;13:1438-1440.
    PubMed     Text format    


  222. SHOLL LM
    Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies.
    J Thorac Oncol. 2018;13:1433-1435.
    PubMed     Text format    


    September 2018
  223. BLUMENTHAL GM, Bunn PA Jr, Chaft JE, McCoach CE, et al
    Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
    J Thorac Oncol. 2018 Sep 27. pii: S1556-0864(18)33129.
    PubMed     Text format    


  224. SURESH K, Voong KR, Shankar B, Forde PM, et al
    Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33118.
    PubMed     Text format     Abstract available


  225. QIN N, Li N, Wang C, Pu Z, et al
    Association of mosaic loss of chromosome Y with lung cancer risk and prognosis in a Chinese population.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33125.
    PubMed     Text format     Abstract available


  226. TOKI MI, Mani N, Smithy JW, Liu Y, et al
    Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33124.
    PubMed     Text format     Abstract available


  227. QIN A, Johnson A, Ross JS, Miller VA, et al
    Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33126.
    PubMed     Text format     Abstract available


  228. FRUH M M, Betticher DC, Stupp R, Xyrafas A, et al
    Multimodal Treatment in Operable Stage III Non-Small Cell Lung Cancer: A Pooled Analysis on Long Term Results of three SAKK trials (SAKK 16/96, 16/00, 16/01).
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33123.
    PubMed     Text format     Abstract available


  229. TSAO AS, Lindwasser OW, Adjei AA, Adusumilli PS, et al
    Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation
    J Thorac Oncol. 2018 Sep 25. pii: S1556-0864(18)33121.
    PubMed     Text format     Abstract available


  230. DE RUYSSCHER D, Wanders R, Hendriks LE, van Baardwijk A, et al
    Progression-Free-Survival and Overall Survival beyond 5 years of non-small cell lung cancer patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450).
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)30935.
    PubMed     Text format     Abstract available


  231. YU H, Chen Z, Ballman K, Watson MA, et al
    Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma.
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33116.
    PubMed     Text format     Abstract available


  232. RAMALINGAM S, Dinan MA, Crawford J
    Survival comparison in patients with Stage IV lung cancer in Academic versus Community Centers in the United States.
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33117.
    PubMed     Text format     Abstract available


  233. GANDARA DR, von Pawel J, Mazieres J, Sullivan R, et al
    Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33043.
    PubMed     Text format     Abstract available


  234. SUN TY, Niu X, Chakraborty A, Neal JW, et al
    Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33046.
    PubMed     Text format    


  235. FERRER L, Giaj Levra M, Brevet M, Antoine M, et al
    A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33044.
    PubMed     Text format     Abstract available


  236. LIN JJ, Chin E, Yeap BY, Ferris LA, et al
    Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33040.
    PubMed     Text format     Abstract available


  237. DESCARPENTRIES C, Lepretre F, Escande F, Kherrouche Z, et al
    Optimization of routine testing for MET exon 14 splice site mutations in non-small cell lung cancer patients.
    J Thorac Oncol. 2018 Sep 6. pii: S1556-0864(18)33038.
    PubMed     Text format     Abstract available


  238. DENG W, Xu T, Wang Y, Xu Y, et al
    Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33036.
    PubMed     Text format     Abstract available


  239. LE-RADEMACHER J, Dahlberg S, Lee JJ, Adjei AA, et al
    Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33034.
    PubMed     Text format     Abstract available


  240. SWAMI U, Smith M, Zhang J
    Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    J Thorac Oncol. 2018;13:e183-e184.
    PubMed     Text format    


  241. MO X, Xu-Welliver M
    Response to the Letter to Editor re: The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e182-e183.
    PubMed     Text format    


  242. WALRAVEN I, Kwint M, Belderbos J
    The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e181-e182.
    PubMed     Text format    


  243. JIN B, Chuang X, Liu Y
    Remarkable Long-Term Efficacy of Nivolumab Immunotherapy in a Chinese Patient with Extensive-Disease Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e174-e177.
    PubMed     Text format    


  244. DENG L, Kiedrowski LA, Ravera E, Cheng H, et al
    Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.
    J Thorac Oncol. 2018;13:e169-e172.
    PubMed     Text format    


  245. XU YJ, Shi ZL, Wang Z, Du L, et al
    Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma.
    J Thorac Oncol. 2018;13:e165-e168.
    PubMed     Text format    


  246. MARINO M, Visca P, Ottaviano M
    PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth".
    J Thorac Oncol. 2018;13:1239-1241.
    PubMed     Text format    


    August 2018
  247. MORO M, Caiola E, Ganzinelli M, Zulato E, et al
    Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Aug 24. pii: S1556-0864(18)32988.
    PubMed     Text format     Abstract available


  248. BORGHAEI H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, et al
    24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Aug 20. pii: S1556-0864(18)30942.
    PubMed     Text format     Abstract available


  249. LAUFER-GEVA S, Rozenblum AB, Twito T, Grinberg R, et al
    The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
    J Thorac Oncol. 2018 Aug 16. pii: S1556-0864(18)30940.
    PubMed     Text format     Abstract available


  250. GUAITOLI G, Baldessari C, Tomasello C, Barbieri F, et al
    Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
    J Thorac Oncol. 2018;13:e152-e153.
    PubMed     Text format    


  251. FUJIOKA S, Kitajima T, Itotani R
    Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib.
    J Thorac Oncol. 2018;13:e137-e139.
    PubMed     Text format    


  252. GARCIA CA, Dacic S, Villaruz LC
    Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e135-e136.
    PubMed     Text format    


  253. HAMANN HA, Pujol JL
    Introduction to the Special Section: The Experience and Impact of Lung Cancer Stigma.
    J Thorac Oncol. 2018;13:1053-1054.
    PubMed     Text format    


    July 2018
  254. SU S, Dong ZY, Xie Z, Yan LX, et al
    Strong PD-L1 expression predicts poor response and de novo resistance to EGFR TKIs among non-small cell lung cancer patients with EGFR mutation.
    J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30811.
    PubMed     Text format     Abstract available


  255. ROACH MC, Robinson CG, DeWees TA, Ganachaud J, et al
    Stereotactic body radiation therapy (SBRT) for central early stage non-small cell lung cancer: results of a prospective phase I/II trial.
    J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30812.
    PubMed     Text format     Abstract available


  256. ZHANG M, Wang Q, Ding Y, Wang G, et al
    Brief Report: CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Jul 13. pii: S1556-0864(18)30785.
    PubMed     Text format     Abstract available


  257. KATO R, Hayashi H, Sano K, Handa K, et al
    Nivolumab-induced hemophilia A presenting as gastric ulcer bleeding in a patient with non-small cell lung cancer.
    J Thorac Oncol. 2018 Jul 11. pii: S1556-0864(18)30779.
    PubMed     Text format    


  258. OCCHIPINTI S, Dunn J, O'Connell DL, Garvey G, et al
    Lung Cancer Stigma Across the Social Network: Patients' and Caregivers' Perspectives.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30766.
    PubMed     Text format     Abstract available


  259. RIESS JW, Gandara DR, Frampton GM, Madison R, et al
    Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30770.
    PubMed     Text format     Abstract available


  260. WILLIAMSON TJ, Choi AK, Kim JC, Garon EB, et al
    A longitudinal investigation of internalized stigma, constrained disclosure, and quality of life across 12 weeks in lung cancer patients on active oncologic treatment.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30769.
    PubMed     Text format     Abstract available


  261. PATIL T, Smith DE, Bunn PA, Aisner DL, et al
    The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30772.
    PubMed     Text format     Abstract available


  262. SEHGAL K, Peters MLB, VanderLaan PA, Rangachari D, et al
    Activity of brigatinib in the setting of alectinib resistance mediated by ALK-I1171S in ALK rearranged lung cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30771.
    PubMed     Text format    


  263. KINSEY E, Ajazi E, Wang X, Johnston MAM, et al
    Predictors of physical and functional loss in advanced stage lung cancer patients receiving platinum chemotherapy.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30676.
    PubMed     Text format     Abstract available


  264. LIU Y, Lusk CM, Cho MH, Silverman EK, et al
    Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30767.
    PubMed     Text format     Abstract available


  265. VELCHETI V, Madison R, Ali SM, Schrock AB, et al
    WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
    J Thorac Oncol. 2018;13:e122-e123.
    PubMed     Text format    


  266. ASSALLUM H, Harris K
    The Impact of the Eighth TNM Classification for Lung Cancer on the Endobronchial Ultrasound Procedure.
    J Thorac Oncol. 2018;13:e119-e120.
    PubMed     Text format    


  267. NAVARRO A, Martinez-Marti A, Felip E
    HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?
    J Thorac Oncol. 2018;13:874-876.
    PubMed     Text format    


    June 2018
  268. WU YL, Lu S, Lu Y, Zhou J, et al
    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jun 29. pii: S1556-0864(18)30721.
    PubMed     Text format     Abstract available


  269. SHIUE K, Cerra-Franco A, Shapiro R, Estabrook N, et al
    Histology, tumor volume, and radiation dose predict outcomes in non-small cell lung cancer patients after stereotactic ablative radiotherapy.
    J Thorac Oncol. 2018 Jun 26. pii: S1556-0864(18)30716.
    PubMed     Text format     Abstract available


  270. LIN JJ, Zhu VW, Schoenfeld AJ, Yeap BY, et al
    Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.
    J Thorac Oncol. 2018 Jun 20. pii: S1556-0864(18)30714.
    PubMed     Text format     Abstract available


  271. WANG S, Yang L, Ci B, Maclean M, et al
    Development and Validation of a Nomogram Prognostic Model for Small-Cell Lung Cancer Patients.
    J Thorac Oncol. 2018 Jun 11. pii: S1556-0864(18)30687.
    PubMed     Text format     Abstract available


  272. HARATAKE N, Tagawa T, Hirai F, Toyokawa G, et al
    Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30681.
    PubMed     Text format    


  273. JONES CC, Mercaldo SF, Blume JD, Wenzlaff AS, et al
    Racial disparities in lung cancer survival: The contribution of stage, treatment, and ancestry.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30682.
    PubMed     Text format     Abstract available


  274. ROLFO C, Mack PC, Scagliotti GV, Baas P, et al
    IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680.
    PubMed     Text format     Abstract available


  275. GERAUD A, Mezquita L, Bigot F, Caramella C, et al
    Long leptomeningeal responses with brigatinib in two heavily pre-treated ALK-rearranged non-small cell lung cancer patients.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30683.
    PubMed     Text format    


  276. PARK S, Ahn BC, Lim SW, Sun JM, et al
    Characteristics and outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
    J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30673.
    PubMed     Text format     Abstract available


  277. YEGYA-RAMAN N, Wang K, Kim S, Reyhan M, et al
    Dosimetric Predictors of Symptomatic Cardiac Events after Conventional-Dose Chemoradiation Therapy for Inoperable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30675.
    PubMed     Text format     Abstract available


  278. WOZNIAK AJ, Schwartz AG
    Risk of Second Lung Cancer in Patients With Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results Data.
    J Thorac Oncol. 2018;13:e106-e107.
    PubMed     Text format    


  279. MASCALCHI M, Sali L
    Risk of Second Lung Cancer in ITALUNG LDCT Screening.
    J Thorac Oncol. 2018;13:e105-e106.
    PubMed     Text format    


  280. WU CK, Kao SJ, Lai HC
    Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations.
    J Thorac Oncol. 2018;13:e103-e105.
    PubMed     Text format    


  281. BONOMI P, Blumenthal G, Ferris AS, Stewart DJ, et al
    Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
    J Thorac Oncol. 2018;13:748-751.
    PubMed     Text format    


  282. TSENG D, Padda SK, Wakelee HA
    Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:741-744.
    PubMed     Text format    


    May 2018
  283. GETTINGER S, Hellmann MD, Chow LQM, Borghaei H, et al
    Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 23. pii: S1556-0864(18)30628.
    PubMed     Text format     Abstract available


  284. HAMANN HA, Ver Hoeve ES, Carter-Harris L, Studts JL, et al
    Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum.
    J Thorac Oncol. 2018 May 22. pii: S1556-0864(18)30627.
    PubMed     Text format     Abstract available


  285. FEHRENBACHER L, von Pawel J, Park K, Rittmeyer A, et al
    Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 May 16. pii: S1556-0864(18)30611.
    PubMed     Text format     Abstract available


  286. GADGEEL SM, Pennell NA, Fidler MJ, Halmos B, et al
    Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC).
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30600.
    PubMed     Text format     Abstract available


  287. SPIGEL DR, Chaft JE, Gettinger S, Chao BH, et al
    FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30603.
    PubMed     Text format     Abstract available


  288. WALTER JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, et al
    New subsolid pulmonary nodules in lung cancer screening: a brief report of the NELSON trial.
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30605.
    PubMed     Text format     Abstract available


  289. KARANTH S, Rajan SS, Sharma G, Yamal JM, et al
    Racial-Ethnic Disparities in End-of-Life Care Quality among Lung Cancer Patients: A SEER-Medicare-Based Study.
    J Thorac Oncol. 2018 May 10. pii: S1556-0864(18)30540.
    PubMed     Text format     Abstract available


  290. CODONY-SERVAT J, Garcia-Roman S, Molina-Vila MA, Bertran-Alamillo J, et al
    Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30592.
    PubMed     Text format     Abstract available


  291. SMYTH RJ, Toomey SM, Sartori A, Hanrahan EO, et al
    Brief report on the detection of the EGFR-T790M mutation in exhaled breath condensate from lung cancer patients.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30595.
    PubMed     Text format     Abstract available


  292. NAKAMURA R, Inage Y, Tobita R, Yoneyama S, et al
    Sarcopenia in resected non-small cell lung cancer: Effect on postoperative outcomes.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30597.
    PubMed     Text format     Abstract available


  293. KATZ SI, Hammer M, Bagley S, Aggarwal C, et al
    Radiologic pseudoprogression during anti-PD1 therapy for advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 May 5. pii: S1556-0864(18)30536.
    PubMed     Text format     Abstract available


  294. VOKES EE, Govindan R, Iscoe N, Hossain AM, et al
    The Impact of Staging by Positron Emission Tomography on Overall Survival and Progression-free Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 4. pii: S1556-0864(18)30589.
    PubMed     Text format     Abstract available


  295. GARASSINO MC, Gelibter AJ, Grossi F, Chiari R, et al
    Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30553.
    PubMed     Text format     Abstract available


  296. TAMURA T, Akimoto E, Matsumoto C, Mori S, et al
    Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30554.
    PubMed     Text format    


  297. SAFIRI S, Ashrafi-Asgarabad A
    Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab: Methodological Issues.
    J Thorac Oncol. 2018;13:e85-e86.
    PubMed     Text format    


  298. WU B
    Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e84-e85.
    PubMed     Text format    


  299. HOYLE C, Dyer M
    Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e83-e84.
    PubMed     Text format    


  300. MARTINEZ VILA C, Garcia Garcia Y, Carcereny Costa E
    Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e77-e79.
    PubMed     Text format    


  301. DRESLER C, Warren GW, Arenberg D, Yang P, et al
    "Teachable Moment" Interventions in Lung Cancer: Why Action Matters.
    J Thorac Oncol. 2018;13:603-605.
    PubMed     Text format    


  302. HERMAN M, Warkentin MT, Shepshelovich D, Latifovic L, et al
    Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All.
    J Thorac Oncol. 2018;13:601-602.
    PubMed     Text format    


  303. TANIZAKI J, Chiba Y, Haratani K, Hayashi H, et al
    In Reply.
    J Thorac Oncol. 2018;13:e86-e87.
    PubMed     Text format    


  304. RANGACHARI D, VanderLaan PA, Costa DB
    Updated Correlation of 22C3-PD-L1 >/=50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting.
    J Thorac Oncol. 2018;13:e81-e83.
    PubMed     Text format    


  305. MIYAWAKI E, Murakami H, Takahashi T
    Correlation between 22C3-PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma.
    J Thorac Oncol. 2018;13:e79-e81.
    PubMed     Text format    


  306. ROSSI A, Novello S
    The Tradition of the Rising Sun: When Geography Counts.
    J Thorac Oncol. 2018;13:598-600.
    PubMed     Text format    


  307. HO C
    Anticipating the Next Step in the Management of ALK-Positive NSCLC.
    J Thorac Oncol. 2018;13:595-597.
    PubMed     Text format    


    April 2018
  308. DUDNIK E, Peled N, Nechushtan H, Wollner M, et al
    BRAF mutant lung cancer: PD-L1 expression, tumor mutational burden, microsatellite instability status and response to immune check-point inhibitors.
    J Thorac Oncol. 2018 Apr 30. pii: S1556-0864(18)30552.
    PubMed     Text format     Abstract available


  309. ANDREANO A, Peake MD, Janes SM, Valsecchi MG, et al
    The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012.
    J Thorac Oncol. 2018 Apr 26. pii: S1556-0864(18)30550.
    PubMed     Text format     Abstract available


  310. VAN KEMPEN LC, Wang H, Aguirre ML, Spatz A, et al
    Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30548.
    PubMed     Text format    


  311. LI Z, Shen L, Ding D, Huang J, et al
    Efficacy of Crizotinib Among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-small-cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30542.
    PubMed     Text format     Abstract available


  312. MUNARI E, Zamboni G, Lunardi G, Marchionni L, et al
    PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsies and whole sections.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30543.
    PubMed     Text format     Abstract available


  313. VAN VEGGEL B, de Langen AJ, Hashemi S, Monkhorst K, et al
    Brief report: Afatinib and cetuximab in four patients with EGFR exon 20 insertion positive advanced non-small-cell lung cancer.
    J Thorac Oncol. 2018 Apr 24. pii: S1556-0864(18)30538.
    PubMed     Text format     Abstract available


  314. SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
    Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30537.
    PubMed     Text format     Abstract available


  315. WADE S, Weber M, Caruana M, Kang YJ, et al
    Estimating the cost-effectiveness of lung cancer screening with low dose computed tomography for high risk smokers in Australia.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30531.
    PubMed     Text format     Abstract available


  316. DONINGTON JS, Kim YT, Tong B, Moreira AL, et al
    Progress in the management of Early Stage Non-Small Cell Lung Cancer in 2017.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30508.
    PubMed     Text format     Abstract available


  317. OWADA-OZAKI Y, Muto S, Takagi H, Inoue T, et al
    Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30509.
    PubMed     Text format     Abstract available


  318. OSTIOS-GARCIA L, Faig J, Leonardi GC, Adeni AE, et al
    Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30270.
    PubMed     Text format     Abstract available


  319. SANDBERG Y, den Bakker MA
    Small cell lung cancer presenting as carcinocythemia.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30269.
    PubMed     Text format    


  320. MA Y, Zheng X, Zhao H, Fang W, et al
    First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30264.
    PubMed     Text format     Abstract available


  321. CARR SR, Akerley W, Cannon-Albright L
    Genetic Contribution to Non-Squamous, Non-Small Cell Lung Cancer in Non-Smokers.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30263.
    PubMed     Text format     Abstract available


  322. WATANABE J, Furuya N, Fujiwara Y
    Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.
    J Thorac Oncol. 2018;13:e66-e69.
    PubMed     Text format    


  323. MORMILE R
    Metformin and Lung Cancer: The Final Blow to the Obesity Paradox?
    J Thorac Oncol. 2018;13:e65-e66.
    PubMed     Text format    


  324. SAFIRI S
    Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity.
    J Thorac Oncol. 2018;13:e61.
    PubMed     Text format    


  325. SANDFELD-PAULSEN B, Aggerholm-Pedersen N
    Response to Safri: "Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity".
    J Thorac Oncol. 2018;13:e61-e62.
    PubMed     Text format    


  326. MASAI K, Motoi N
    Response to Letter to the Editor Titled "Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer".
    J Thorac Oncol. 2018;13:e58-e59.
    PubMed     Text format    


  327. MANSORI K, Ayubi E, Safiri S
    Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer.
    J Thorac Oncol. 2018;13:e57-e58.
    PubMed     Text format    


  328. SUN JM
    Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2018;13:e56-e57.
    PubMed     Text format    


  329. COSTANTINI A, Cadranel J
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e55-e56.
    PubMed     Text format    


  330. LEVY A, Hendriks LE, Faivre-Finn C
    Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?
    J Thorac Oncol. 2018;13:475-477.
    PubMed     Text format    


  331. SENAN S, Rusthoven CG, Slotman BJ, Siva S, et al
    Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017.
    J Thorac Oncol. 2018;13:488-496.
    PubMed     Text format     Abstract available


    March 2018
  332. GAJRA A, Zemla TJ, Jatoi A, Feliciano JL, et al
    Time-to-Treatment-Failure and Related Outcomes among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients.
    J Thorac Oncol. 2018 Mar 30. pii: S1556-0864(18)30254.
    PubMed     Text format     Abstract available


  333. LI Y, Liu B, Connolly ID, Kakusa BW, et al
    Brief Report: Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
    J Thorac Oncol. 2018 Mar 28. pii: S1556-0864(18)30222.
    PubMed     Text format     Abstract available


  334. SHIBAHARA D, Tanaka K, Iwama E, Kubo N, et al
    Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 26. pii: S1556-0864(18)30215.
    PubMed     Text format     Abstract available


  335. LEE CK, Lord S, Marschner I, Wu YL, et al
    The value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer.
    J Thorac Oncol. 2018 Mar 23. pii: S1556-0864(18)30212.
    PubMed     Text format     Abstract available


  336. FLORES R, Taioli E, Yankelevitz DF, Becker BJ, et al
    Initiative for Early Lung Cancer Research on Treatment: Development of Study Design and Pilot Implementation.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30211.
    PubMed     Text format     Abstract available


  337. GETTINGER SN, Wurtz A, Goldberg SB, Rimm D, et al
    Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in Twenty-Six Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30210.
    PubMed     Text format     Abstract available


  338. MAENG CH, Song JU, Shim SR, Lee J, et al
    The Role of Prophylactic Cranial Irradiation in Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30180.
    PubMed     Text format     Abstract available


  339. PARRA ER, Villalobos P, Zhang J, Behrens C, et al
    Immunohistochemical and Image Analysis-based Study Demonstrate that Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30182.
    PubMed     Text format     Abstract available


  340. ROCCO G, Pennazza G, Santonico M, Longo F, et al
    Breathprinting and early diagnosis of lung cancer.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30183.
    PubMed     Text format     Abstract available


  341. SPIGEL DR, Reynolds C, Waterhouse D, Garon EB, et al
    Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation-Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
    J Thorac Oncol. 2018 Mar 5. pii: S1556-0864(18)30176.
    PubMed     Text format     Abstract available


  342. TOYOOKA S, Okumura N, Nakamura H, Nakata M, et al
    A multi-center randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer.
    J Thorac Oncol. 2018 Mar 2. pii: S1556-0864(18)30168.
    PubMed     Text format     Abstract available


  343. YASUDA Y, Ozasa H, Kim YH
    PD-L1 Expression in Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e40-e41.
    PubMed     Text format    


  344. CHO JH, Sun JM, Lee SH, Ahn JS, et al
    Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e34-e36.
    PubMed     Text format    


  345. RANDHAWA S, Moore RF, DiSesa V, Kaiser L, et al
    Role of Thoracic Surgeons in Lung Cancer Screening: Opportune Time for Involvement.
    J Thorac Oncol. 2018;13:298-300.
    PubMed     Text format    


  346. FAN J, Dai X, Nie X
    Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.
    J Thorac Oncol. 2018;13:e45-e48.
    PubMed     Text format    


  347. YIN J, Zhang Y, Zhang Y, Peng F, et al
    Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib.
    J Thorac Oncol. 2018;13:e43-e45.
    PubMed     Text format    


  348. RIHAWI K, Cinausero M, Fiorentino M, Salvagni S, et al
    Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins.
    J Thorac Oncol. 2018;13:e41-e43.
    PubMed     Text format    


  349. RAEZ LE, Pinto JA, Schrock AB, Ali SM, et al
    EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
    J Thorac Oncol. 2018;13:e33-e34.
    PubMed     Text format    


    February 2018
  350. GIROUX DJ, Van Schil P, Asamura H, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: A Renewed Call to Participation.
    J Thorac Oncol. 2018 Feb 21. pii: S1556-0864(18)30131.
    PubMed     Text format     Abstract available


  351. WEN J, Liu H, Wang L, Wang X, et al
    Potentially Functional variants of ATG16L2 predict radiation pneumonitis and outcomes in patients with non-small cell lung cancer after definitive radiotherapy.
    J Thorac Oncol. 2018 Feb 15. pii: S1556-0864(18)30103.
    PubMed     Text format     Abstract available


  352. VAN DE GOOR R, van Hooren M, Dingemans AM, Kremer B, et al
    Training and validating a portable electronic nose for lung cancer screening.
    J Thorac Oncol. 2018 Feb 6. pii: S1556-0864(18)30093.
    PubMed     Text format     Abstract available


  353. EATON KD, Romine PE, Goodman GE, Thornquist MD, et al
    Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.
    J Thorac Oncol. 2018 Feb 2. pii: S1556-0864(18)30090.
    PubMed     Text format     Abstract available


  354. MORGENSZTERN D, Samson P, Waqar SN, Devarakonda S, et al
    Early mortality in patients undergoing adjuvant chemotherapy for non-small-cell lung cancer.
    J Thorac Oncol. 2018 Feb 1. pii: S1556-0864(18)30036.
    PubMed     Text format     Abstract available


  355. ASHRAFI-ASGARABAD A, Safiri S
    Prognostic Value of Primary Tumor Volume Changes on Kilovoltage Onboard Cone Beam Computed Tomography during Definitive Chemoradiotherapy for stage III Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2018;13:e26-e27.
    PubMed     Text format    


  356. LEONE A
    C797S and T790M EGFR Mutations in Non-Small Cell Lung Cancer: In Trans or in Separate Clones?
    J Thorac Oncol. 2018;13:e21-e22.
    PubMed     Text format    


  357. GAZDAR AF
    Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them?
    J Thorac Oncol. 2018;13:148-150.
    PubMed     Text format    


    January 2018
  358. KATZMAN D, Wu S, Sterman DH
    Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review.
    J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30079.
    PubMed     Text format     Abstract available


  359. WOLFF HB, Alberts L, Kastelijn EA, Lissenberg-Witte BI, et al
    Differences in longitudinal health utility between stereotactic body radiation therapy and surgery in stage I non-small cell lung cancer.
    J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30083.
    PubMed     Text format     Abstract available


  360. HUBBELING HG, Schapira EF, Horick NK, Goodwin KEH, et al
    Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jan 26. pii: S1556-0864(18)30039.
    PubMed     Text format     Abstract available


  361. STONE E, Jett J, Warren G, Cummings KM, et al
    Cannabis Use, Lung Cancer, and Related Issues.
    J Thorac Oncol. 2018 Jan 24. pii: S1556-0864(18)30038.
    PubMed     Text format     Abstract available


  362. LINDEMAN NI, Cagle PT, Aisner DL, Arcila ME, et al
    Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and
    J Thorac Oncol. 2018 Jan 23. pii: S1556-0864(17)33071.
    PubMed     Text format     Abstract available


  363. HOUSTON KA, Mitchell KA, King J, White A, et al
    Histologic Lung Cancer Incidence Rates and Trends vary by Race/Ethnicity and Residential County.
    J Thorac Oncol. 2018 Jan 19. pii: S1556-0864(18)30003.
    PubMed     Text format     Abstract available


  364. NYGARD L, Vogelius IR, Fischer BM, Kjaer A, et al
    A competing risk model of first failure site after definitive (chemo) radiation therapy for locally advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Jan 18. pii: S1556-0864(18)30006.
    PubMed     Text format     Abstract available


  365. MAROM EM, Ofek E, Bekker E, Onn A, et al
    Tattoo Induced False Positive FDG PET-CT Interpretation while Staging for Lung Cancer.
    J Thorac Oncol. 2018 Jan 17. pii: S1556-0864(18)30005.
    PubMed     Text format    


  366. RICCIUTI B, Metro G, Brambilla M, Ludovini V, et al
    Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.
    J Thorac Oncol. 2018;13:e9-e12.
    PubMed     Text format    


  367. MCCANN B, Clark B
    Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor-Mutated Lung Cancer Treated with Two Cycles of Erlotinib.
    J Thorac Oncol. 2018;13:e7-e8.
    PubMed     Text format    


  368. ZHANG X, Zheng X
    Reply to "Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?"
    J Thorac Oncol. 2018;13:e16.
    PubMed     Text format    


  369. MORMILE R
    Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?
    J Thorac Oncol. 2018;13:e15.
    PubMed     Text format    


  370. DONG ZY, Zhang C, Li YF, Su J, et al
    Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
    J Thorac Oncol. 2018;13:85-96.
    PubMed     Text format     Abstract available


  371. BUCCIARELLI PR, Tan KS, Chudgar NP, Brandt W, et al
    BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
    J Thorac Oncol. 2018;13:73-84.
    PubMed     Text format     Abstract available


  372. PATIL NS, Righi L, Koeppen H, Zou W, et al
    Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2018;13:124-133.
    PubMed     Text format     Abstract available


  373. NOONAN SA, Patil T, Gao D, King GG, et al
    Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
    J Thorac Oncol. 2018;13:134-138.
    PubMed     Text format     Abstract available


  374. SALVI S, Ravetti JL, Arena G, Musso C, et al
    Evaluation of RET Gene Rearrangement by Fluorescence In Situ Hybridization in Malignant Mesothelioma.
    J Thorac Oncol. 2018;13:e12-e14.
    PubMed     Text format    


  375. AHN MJ
    Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?
    J Thorac Oncol. 2018;13:10-11.
    PubMed     Text format    


    December 2017
  376. PILOTTO S, Sperduti I, Leuzzi G, Chiappetta M, et al
    Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33101.
    PubMed     Text format     Abstract available


  377. WU SP, Liao RQ, Tu HY, Wang WJ, et al
    Stromal PD-L1+regulatory T cells and PD-1+CD8+ T cells define the response of different subsets of non-small-cell lung cancer to PD-1/PD-L1 blockade immunotherapy.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33102.
    PubMed     Text format     Abstract available


  378. ROBIN TP, Camidge DR, Stuhr K, Nath SK, et al
    Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33107.
    PubMed     Text format     Abstract available


  379. MILLER ED, Fisher JL, Haglund KE, Grecula JC, et al
    The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non-small cell lung cancer.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33108.
    PubMed     Text format     Abstract available


  380. FELIP E, Barlesi F, Besse B, Chu Q, et al
    Brief Report: Phase 2 Study of the HSP-90 inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 13. pii: S1556-0864(17)33083.
    PubMed     Text format     Abstract available


  381. TSENG YH, Ho HL, Lai CR, Luo YH, et al
    Brief Report: PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion.
    J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33079.
    PubMed     Text format     Abstract available


  382. AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
    Influence of Ground-Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33080.
    PubMed     Text format     Abstract available


  383. STIEFEL F, Bourquin C
    Adverse Effects of "Teachable Moment" Interventions in Lung Cancer: Why Prudence Matters.
    J Thorac Oncol. 2017 Dec 11. pii: S1556-0864(17)32862.
    PubMed     Text format    


  384. STABILE LP, Farooqui M, Kanterewicz B, Abberbock S, et al
    Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.
    J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33076.
    PubMed     Text format     Abstract available


  385. FUJIMOTO D, Sato Y, Uehara K, Ishida K, et al
    Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung cancer.
    J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33072.
    PubMed     Text format     Abstract available


  386. HOTTA K, Aoe K, Kozuki T, Ohashi K, et al
    A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 4. pii: S1556-0864(17)33065.
    PubMed     Text format     Abstract available


  387. BOLZACCHINI E, Tuzi A, Gobba S, Pinotti G, et al
    Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer.
    J Thorac Oncol. 2017;12:e208-e210.
    PubMed     Text format    


  388. GU F, Cheung L, Katki H, Caporaso N, et al
    Response to Safiri et al. "Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening".
    J Thorac Oncol. 2017;12:e208.
    PubMed     Text format    


  389. SAFIRI S, Mansourpour H, Ayubi E
    Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers For Lung Cancer Screening.
    J Thorac Oncol. 2017;12:e207.
    PubMed     Text format    


  390. NAKANISHI Y, Masuda S, Iida Y, Takahashi N, et al
    Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
    J Thorac Oncol. 2017;12:e202-e204.
    PubMed     Text format    



  391. Erratum to: Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim S-M, et al. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Postive Human Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(3):491-500.
    J Thorac Oncol. 2017;12:1859.
    PubMed     Text format    


  392. WATZA D, Schwartz AG
    Addressing Underrepresented Populations in Lung Cancer Research: The Hispanic/Latino Lung Cancer Registry Identifies Distinct Mutation Profiles for NSCLC.
    J Thorac Oncol. 2017;12:1744-1745.
    PubMed     Text format    


    November 2017
  393. SOCINSKI MA, Obasaju C, Gandara D, Hirsch FR, et al
    Current and Emergent Therapy Options for Advanced Squamous-Cell Lung Cancer.
    J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33053.
    PubMed     Text format     Abstract available


  394. HENDRY S, Byrne DJ, Wright GM, Young RJ, et al
    Comparison of four PD-L1 immunohistochemical assays in lung cancer.
    J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33054.
    PubMed     Text format     Abstract available


  395. TANIZAKI J, Haratani K, Hayashi H, Chiba Y, et al
    Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab.
    J Thorac Oncol. 2017 Nov 20. pii: S1556-0864(17)33008.
    PubMed     Text format     Abstract available


  396. YANKELEVITZ DF
    CT Screening for Lung Cancer: Successful Trial, but Failed Understanding.
    J Thorac Oncol. 2017 Nov 18. pii: S1556-0864(17)32767.
    PubMed     Text format    


  397. RECK M, Taylor F, Penrod JR, DeRosa M, et al
    Impact of Nivolumab Versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients With Advanced Squamous Non-Small Cell Lung Cancer: Results From the CheckMate 017 Study.
    J Thorac Oncol. 2017 Nov 9. pii: S1556-0864(17)32878.
    PubMed     Text format     Abstract available


  398. FERRARA R, Auger N, Auclin E, Besse B, et al
    Clinical and translational implications of RET rearrangements in non-small cell lung cancer.
    J Thorac Oncol. 2017 Nov 8. pii: S1556-0864(17)32866.
    PubMed     Text format     Abstract available


  399. RICORDEL C, Llamas-Gutierrez F, Chiforeanu D, Lena H, et al
    Large Cell Neuroendocrine Lung Carcinoma Transformation as an Acquired Resistance Mechanism to Osimertinib.
    J Thorac Oncol. 2017;12:e184-e186.
    PubMed     Text format    


  400. LEE JS, Hur JY, Kim HJ, Lee KY, et al
    A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e179-e181.
    PubMed     Text format    


  401. HENNINGFIELD MF, Adjei AA
    Lung Cancer Awareness Month-A Lot of Progress, But More Work Needs to Be Done.
    J Thorac Oncol. 2017;12:1603-1605.
    PubMed     Text format    


    October 2017
  402. PARK SE, Lee SH, Ahn JS, Ahn MJ, et al
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32850.
    PubMed     Text format     Abstract available


  403. WU B, Gu X, Zhang Q
    Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32851.
    PubMed     Text format     Abstract available


  404. SANDFELD-PAULSEN B, Meldgaard P, Aggerholm-Pedersen N
    Comorbidity in lung cancer: A prospective cohort study of self-reported versus register-based comorbidity.
    J Thorac Oncol. 2017 Oct 19. pii: S1556-0864(17)32788.
    PubMed     Text format     Abstract available


  405. PINATO DJ, Newsom-Davis T
    Regression of para-neoplastic rash following lung cancer chemotherapy.
    J Thorac Oncol. 2017 Oct 14. pii: S1556-0864(17)32786.
    PubMed     Text format    


  406. TOKACA N, Barth S, O'Brien M, Bhosle J, et al
    Molecular adequacy of image-guided rebiopsies for molecular retesting in advanced non-small cell lung cancer: a single centre experience.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32760.
    PubMed     Text format     Abstract available


  407. THAKUR MK, Ruterbusch JJ, Schwartz AG, Gadgeel SM, et al
    Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology and End Results (SEER) Data.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32766.
    PubMed     Text format     Abstract available


  408. SHUKUYA T, Patel S, Shane-Carson K, He K, et al
    Lung Cancer Patients with Germline Mutations detected by next generation sequencing and/or liquid biopsy.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32764.
    PubMed     Text format    


  409. SHOLL LM
    Next-Generation Sequencing from Liquid Biopsies in Lung Cancer Patients: Advances in Comprehensive Biomarker Testing.
    J Thorac Oncol. 2017;12:1464-1466.
    PubMed     Text format    


    September 2017
  410. SUN JM, Noh JM, Oh D, Kim HK, et al
    Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32708.
    PubMed     Text format     Abstract available


  411. MEYER M, Vliegenthart R, Henzler T, Buergy D, et al
    Management of progressive pulmonary nodules found during and outside of CT lung cancer screening studies.
    J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32713.
    PubMed     Text format     Abstract available


  412. BOYER MJ, Williams CD, Harpole DH, Onaitis MW, et al
    Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis.
    J Thorac Oncol. 2017 Sep 23. pii: S1556-0864(17)32706.
    PubMed     Text format     Abstract available


  413. ALMODOVAR K, Iams WT, Meador CB, Zhao Z, et al
    Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse.
    J Thorac Oncol. 2017 Sep 22. pii: S1556-0864(17)32705.
    PubMed     Text format     Abstract available


  414. TERAOKA S, Fujimoto D, Morimoto T, Kawachi H, et al
    Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study.
    J Thorac Oncol. 2017 Sep 19. pii: S1556-0864(17)30825.
    PubMed     Text format     Abstract available


  415. HIGGINS KA, Pillai RN, Chen Z, Tian S, et al
    Concomitant chemotherapy and radiotherapy with SBRT Boost for Unresectable, Stage III Non-small Cell Lung Cancer: A phase I Study.
    J Thorac Oncol. 2017 Sep 12. pii: S1556-0864(17)30734.
    PubMed     Text format     Abstract available


  416. GIMBRONE NT, Sarcar B, Gordian ER, Rivera JI, et al
    Brief Report: Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.
    J Thorac Oncol. 2017 Sep 11. pii: S1556-0864(17)30731.
    PubMed     Text format     Abstract available


  417. MASAI K, Sakurai H, Sukeda A, Suzuki S, et al
    Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer.
    J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30727.
    PubMed     Text format     Abstract available


  418. RUSTHOVEN CG, Kavanagh BD
    Prophylactic Cranial Irradiation (PCI) vs Active MRI Surveillance for Small-Cell Lung Cancer: The Case for Equipoise.
    J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30728.
    PubMed     Text format     Abstract available


  419. SEPESI B, Correa AM, Dmitrovsky E, Liu X, et al
    Reply to "Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues".
    J Thorac Oncol. 2017;12:e150-e151.
    PubMed     Text format    


  420. SAFIRI S, Khazaei S, Ayubi E
    The Influence of Body Mass Index on Overall Survival following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2017;12:e149-e150.
    PubMed     Text format    


  421. KHUNGER M, Calabrese C, Kontzias A, Velcheti V, et al
    To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis.
    J Thorac Oncol. 2017;12:e147-e149.
    PubMed     Text format    


  422. KOMATSU T, Nakamura K, Kawase A
    Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
    J Thorac Oncol. 2017;12:e143-e144.
    PubMed     Text format    


  423. FUNAZO T, Nomizo T, Kim YH
    Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    J Thorac Oncol. 2017;12:e140-e141.
    PubMed     Text format    


  424. GORTAIS H, Daniel C, Bidard FC, Jeannot E, et al
    T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.
    J Thorac Oncol. 2017;12:e138-e139.
    PubMed     Text format    


  425. EZE C, Roengvoraphoj O, Manapov F
    Prophylactic Cranial Irradiation in Resected Small Cell Lung Cancer: Comprehensive Staging, Adjuvant Chemotherapy, and Strict Stratification of Pathological Stage Play a Role.
    J Thorac Oncol. 2017;12:e137-e138.
    PubMed     Text format    


  426. VAN SCHIL PE
    Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?
    J Thorac Oncol. 2017;12:1338-1340.
    PubMed     Text format    


    August 2017
  427. WALD P, Mo X, Barney C, Gunderson D, et al
    Prognostic value of primary tumor volume changes on kV-CBCT during definitive chemoradiotherapy for stage III non-small cell lung cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30685.
    PubMed     Text format     Abstract available


  428. ARULANANDA S, Do H, Musafer A, Mitchell P, et al
    Combination osimertinib and gefitinib in C797S and T790M EGFR mutated non-small-cell lung cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30681.
    PubMed     Text format     Abstract available


  429. DAVID EA, Clark JM, Cooke DT, Melnikow J, et al
    The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30683.
    PubMed     Text format     Abstract available


  430. GU F, Cheung LC, Freedman ND, Katki HA, et al
    Potential impact of including Time to First Cigarette into risk models for selecting ever-smokers for lung-cancer screening.
    J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30664.
    PubMed     Text format     Abstract available


  431. LIN JJ, Shaw AT
    Recent Advances in Targeting ROS1 in Lung Cancer.
    J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30668.
    PubMed     Text format     Abstract available


  432. KONO M, Allen PK, Lin SH, Wei X, et al
    Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.
    J Thorac Oncol. 2017 Aug 10. pii: S1556-0864(17)30661.
    PubMed     Text format     Abstract available


  433. XIZHAO S, Wei J, Haiqing C, Fan Y, et al
    Validation of the stage groupings in the 8th edition of the TNM classification for lung cancer.
    J Thorac Oncol. 2017 Aug 3. pii: S1556-0864(17)30659.
    PubMed     Text format     Abstract available


  434. SAFIRI S, Ayubi E
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2017;12:e130-e131.
    PubMed     Text format    


  435. KIMURA H, Tounai Y, Nagato K, Morimoto JI, et al
    A Case of Heart Failure after Treatment with Anti-PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e128-e130.
    PubMed     Text format    


  436. YANAGISAWA S, Miyauchi E, Ichinose M
    Numb Chin Syndrome: An Ominous Sign of Lung Cancer.
    J Thorac Oncol. 2017;12:e114-e116.
    PubMed     Text format    


  437. SHOJAEE S, Vachani A, Nana-Sinkam P
    The Financial Implications of Lung Cancer Screening: Is It Worth It?
    J Thorac Oncol. 2017;12:1177-1179.
    PubMed     Text format    


  438. STONE E, Slatore CG
    The Obesity Paradox-What Does It Mean for Lung Cancer Surgery?
    J Thorac Oncol. 2017;12:1174-1176.
    PubMed     Text format    


    July 2017
  439. FURUTA H, Yoshida T, Shimizu J, Tomita N, et al
    Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Jul 31. pii: S1556-0864(17)30656.
    PubMed     Text format    


  440. ZHANG X, Liu Y, Shao H, Zheng X, et al
    Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications.
    J Thorac Oncol. 2017 Jul 27. pii: S1556-0864(17)30619.
    PubMed     Text format     Abstract available


  441. LI C, Huang C, Mok TS, Zhuang W, et al
    Comparison of 22C3-PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer.
    J Thorac Oncol. 2017 Jul 24. pii: S1556-0864(17)30612.
    PubMed     Text format     Abstract available


  442. NORSKOV MS, Dahl M, Tybjaerg-Hansen A
    Genetic variation in GSTP1, lung function, risk of lung cancer and mortality in 66,000 individuals.
    J Thorac Oncol. 2017 Jul 21. pii: S1556-0864(17)30605.
    PubMed     Text format     Abstract available


  443. LOGANADANE G, Hendriks L, Le Pechoux C, Levy A, et al
    The current role of whole brain radiation therapy in non-small cell lung cancer patients.
    J Thorac Oncol. 2017 Jul 18. pii: S1556-0864(17)30585.
    PubMed     Text format     Abstract available


  444. CHO BC, Kim DW, Bearz A, Laurie SA, et al
    ASCEND-8: A Randomized Phase 1 Study of Ceritinib 450 mg or 600 mg Taken With a Low-Fat Meal Versus 750 mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2017 Jul 17. pii: S1556-0864(17)30578.
    PubMed     Text format     Abstract available


  445. SHLOMI D, Abud M, Liran O, Bar J, et al
    Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.
    J Thorac Oncol. 2017 Jul 11. pii: S1556-0864(17)30573.
    PubMed     Text format     Abstract available


  446. YANG JC, Ou SI, De Petris L, Gadgeel S, et al
    Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Jul 5. pii: S1556-0864(17)30570.
    PubMed     Text format     Abstract available


  447. YOSHIDA R, Sasaki T, Ohsaki Y
    EGFR and KRAS Mutations in Triple-Mutated Lung Cancer.
    J Thorac Oncol. 2017;12:e92-e93.
    PubMed     Text format    


    June 2017
  448. GORE EM, Hu C, Sun AY, Grimm DF, et al
    Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC): NRG Oncology RTOG 0937.
    J Thorac Oncol. 2017 Jun 22. pii: S1556-0864(17)30468.
    PubMed     Text format     Abstract available


  449. GUPTA A, Saltarski JM, White MA, Scaglioni PP, et al
    Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.
    J Thorac Oncol. 2017 Jun 21. pii: S1556-0864(17)30466.
    PubMed     Text format     Abstract available


  450. BARON AE, Kako S, Feser WJ, Malinowski H, et al
    Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.
    J Thorac Oncol. 2017 Jun 17. pii: S1556-0864(17)30461.
    PubMed     Text format     Abstract available


  451. EDELMAN MJ, Hu C, Le QT, Donington JS, et al
    Randomized Phase II Study of Preoperative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-small Cell Lung Cancer: NRG Oncology RTOG 0839.
    J Thorac Oncol. 2017 Jun 16. pii: S1556-0864(17)30459.
    PubMed     Text format     Abstract available


  452. EVISON M, Clive A, Castle L, Powell H, et al
    Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group.
    J Thorac Oncol. 2017 Jun 14. pii: S1556-0864(17)30448.
    PubMed     Text format     Abstract available


  453. AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
    Clinical and Pathological Staging Validation in the Eighth Edition of TNM Classification for Lung Cancer: Correlation Between Solid Size on Thin-section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification.
    J Thorac Oncol. 2017 Jun 13. pii: S1556-0864(17)30444.
    PubMed     Text format     Abstract available


  454. SACHER AG, Komatsubara KM, Oxnard GR
    Application of plasma genotyping technologies in non-small cell lung cancer: a practical review.
    J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30441.
    PubMed     Text format     Abstract available


  455. RANGACHARI D, Le X, Shea M, Huberman MS, et al
    Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy.
    J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30440.
    PubMed     Text format    


  456. LEVENTAKOS K, Peikert T, Midthun D, Molina JR, et al
    Management of multifocal lung cancer: Results of a survey.
    J Thorac Oncol. 2017 Jun 2. pii: S1556-0864(17)30421.
    PubMed     Text format     Abstract available


  457. CHIC N, Mayo-de-Las-Casas C, Reguart N
    Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
    J Thorac Oncol. 2017;12:e78-e80.
    PubMed     Text format    


  458. HSU CL, Chen KY, Kuo SW, Chang YL, et al
    Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    J Thorac Oncol. 2017;12:e75-e76.
    PubMed     Text format    


  459. CHEN CW, Kuo CW, Chen YL, Ho CL, et al
    Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.
    J Thorac Oncol. 2017;12:e72-e74.
    PubMed     Text format    


  460. UGUEN A, Schick U, Quere G
    A Rare Case of ROS1 and ALK Double Rearranged Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e71-e72.
    PubMed     Text format    


  461. THUNNISSEN E, Witte BI, Noguchi M, Yatabe Y, et al
    Reply to Letter "The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases."
    J Thorac Oncol. 2017;12:e70-e71.
    PubMed     Text format    


  462. SABOUR S
    Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer; Statistical Issue on Reproducibility Analysis.
    J Thorac Oncol. 2017;12:e69.
    PubMed     Text format    


  463. GREEN S, Dawe DE, Banerji S
    Immune Signatures of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:913-915.
    PubMed     Text format    


  464. FARUKI H, Mayhew GM, Serody JS, Hayes DN, et al
    Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    J Thorac Oncol. 2017;12:943-953.
    PubMed     Text format     Abstract available


  465. SHAIKH F, Zauderer MG, von Reibnitz D, Wu AJ, et al
    Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2017;12:993-1000.
    PubMed     Text format     Abstract available


  466. SCHROCK AB, Li SD, Frampton GM, Suh J, et al
    Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    J Thorac Oncol. 2017;12:932-942.
    PubMed     Text format     Abstract available


  467. VERRI C, Borzi C, Holscher T, Dugo M, et al
    Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers.
    J Thorac Oncol. 2017;12:922-931.
    PubMed     Text format     Abstract available


    May 2017
  468. SEPESI B, Gold KA, Correa AM, Heymach JV, et al
    The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30390.
    PubMed     Text format     Abstract available


  469. WAN R, Wang Z, Lee JJ, Wang S, et al
    Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small-cell lung cancer.
    J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30391.
    PubMed     Text format     Abstract available


  470. KARLSSON A, Brunnstrom H, Micke P, Veerla S, et al
    Gene expression profiling of large cell lung cancer links transcriptional phenotypes to the new histological WHO2015 classification.
    J Thorac Oncol. 2017 May 20. pii: S1556-0864(17)30388.
    PubMed     Text format     Abstract available


  471. FELLER-KOPMAN D, Liu S, Geisler BP, DeCamp MM, et al
    Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30364.
    PubMed     Text format     Abstract available


  472. CRESSMAN S, Peacock SJ, Tammemagi MC, Evans WK, et al
    The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30354.
    PubMed     Text format     Abstract available


  473. ADAMS MN, Burgess JT, He Y, Gately K, et al
    Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer.
    J Thorac Oncol. 2017 May 6. pii: S1556-0864(17)30351.
    PubMed     Text format     Abstract available


  474. GONG X, Li X, Jiang T, Xie H, et al
    Combined Radiotherapy and anti-PD-L1 antibody Synergistically Enhances Anti-tumor Effect in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 May 3. pii: S1556-0864(17)30343.
    PubMed     Text format     Abstract available


  475. MIYAUCHI E, Ichinose M, Inoue A
    Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.
    J Thorac Oncol. 2017;12:e59-e61.
    PubMed     Text format    


  476. DAHELE M, Damhuis R
    The Relationship between Histology, Stage, and Type of Treatment in Patients with Early-Stage Lung Cancer.
    J Thorac Oncol. 2017;12:e58-e59.
    PubMed     Text format    


  477. RICCIUTI B, Metro G, Baglivo S, Colabrese D, et al
    Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e51-e55.
    PubMed     Text format    


  478. OGATA H, Yamamoto Y, Harada T, Nakanishi Y, et al
    Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e46-e47.
    PubMed     Text format    


  479. ABDUL KARIM L, Wang P, Chahine J, Kallakury B, et al
    Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress.
    J Thorac Oncol. 2017;12:e45.
    PubMed     Text format    


  480. THORNE-NUZZO T, Williams C, Catallini A, Clements J, et al
    A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    J Thorac Oncol. 2017;12:804-813.
    PubMed     Text format     Abstract available


  481. ZHAO ZR, Situ DR, Lau RWH, Mok TSK, et al
    Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas.
    J Thorac Oncol. 2017;12:890-896.
    PubMed     Text format     Abstract available


  482. RANGACHARI D, VanderLaan PA, Shea M, Le X, et al
    Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:878-883.
    PubMed     Text format     Abstract available


  483. SAXON JA, Sholl LM, Janne PA
    EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
    J Thorac Oncol. 2017;12:884-889.
    PubMed     Text format     Abstract available


  484. REULING EMBP, Dickhoff C, Daniels JMA
    Treatment of Bronchial Carcinoid Tumors: Is Surgery Really Necessary?
    J Thorac Oncol. 2017;12:e57-e58.
    PubMed     Text format    


  485. LANTUEJOUL S, Le Stang N, Damiola F, Scherpereel A, et al
    PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
    J Thorac Oncol. 2017;12:778-781.
    PubMed     Text format    


  486. SAVIC S, Rothschild S, Bubendorf L
    Lonely Driver ROS1.
    J Thorac Oncol. 2017;12:776-777.
    PubMed     Text format    


  487. BOTLING J, Sandelin M
    Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction.
    J Thorac Oncol. 2017;12:770-772.
    PubMed     Text format    


    April 2017
  488. CHANSKY K, Detterbeck FC, Nicholson AG, Rusch VW, et al
    The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30340.
    PubMed     Text format     Abstract available


  489. RECK M, Blais N, Juhasz E, Gorbunova V, et al
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30338.
    PubMed     Text format     Abstract available


  490. JENKINS S, C-H Yang J, Ramalingam SS, Yu K, et al
    Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 17. pii: S1556-0864(17)30280.
    PubMed     Text format     Abstract available


  491. SOO RA, Adjei AA
    Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.
    J Thorac Oncol. 2017;12:602-606.
    PubMed     Text format    


  492. GARDNER EE, Poirier JT, Rudin CM
    Histone Code Aberrancies in Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:599-601.
    PubMed     Text format    


  493. PETERS MLB, Costa DB, Rangachari D
    Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.
    J Thorac Oncol. 2017;12:e35-e36.
    PubMed     Text format    


  494. LAINE A, Choy H
    Single-Fraction Carbon Ion Radiotherapy for Early-Stage NSCLC-The Future Is Now.
    J Thorac Oncol. 2017;12:610-611.
    PubMed     Text format    


  495. JOHN T, Russell PA, Thapa B
    Is Mesothelioma in China Rare or Misdiagnosed?
    J Thorac Oncol. 2017;12:607-609.
    PubMed     Text format    


    March 2017
  496. SENAN S, Louie AV
    Correlation, Causation and Confounding-What Is the True Risk of Lung Cancer following Breast Cancer Radiotherapy?
    J Thorac Oncol. 2017 Mar 22. pii: S1556-0864(17)30127.
    PubMed     Text format    


  497. YANAGAWA N
    The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma: Author's Reply.
    J Thorac Oncol. 2017;12:e25-e26.
    PubMed     Text format    


  498. MAO R, Chen C, Fei K
    The Clinical Implications and Thoughts on Different Patterns in Resected Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:e24-e25.
    PubMed     Text format    


    February 2017
  499. WARTH A, Beasley MB, Mino-Kenudson M
    Breaking New Ground: The Evolving Concept of Spread through Air Spaces (STAS).
    J Thorac Oncol. 2017;12:176-178.
    PubMed     Text format    


  500. HEIGENER DF, Reck M
    PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
    J Thorac Oncol. 2017;12:171-172.
    PubMed     Text format    


    January 2017
  501. BASSE C, Merveilleux du Vignaux C, Girard N
    Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit in the Setting of the Future Adoption of the IASLC-ITMIG TNM-Based Staging System.
    J Thorac Oncol. 2017;12:e8-e9.
    PubMed     Text format    


  502. RUSSO A, Franchina T, Ricciardi GRR, Adamo V, et al
    Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.
    J Thorac Oncol. 2017;12:e6-e8.
    PubMed     Text format    


  503. LI YS, Jiang BY, Yang JJ, Tu HY, et al
    Little Influence of Bevacizumab in Diagnosis of Leptomeningeal Metastases in Current Study.
    J Thorac Oncol. 2017;12:e5-e6.
    PubMed     Text format    


  504. VENNIYOOR A
    False-Negative MRI Findings for Leptomeningeal Metastases with Use of Bevacizumab.
    J Thorac Oncol. 2017;12:e5.
    PubMed     Text format    


  505. SOLOMON B
    Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC.
    J Thorac Oncol. 2017;12:9-11.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: